Prolensa FDA Approval History
FDA Approved: Yes (First approved April 5, 2013)
Brand name: Prolensa
Generic name: bromfenac
Dosage form: Ophthalmic Solution
Company: Bausch + Lomb
Treatment for: Postoperative Ocular Inflammation
Prolensa (bromfenac ophthalmic solution) is a topical nonsteroidal anti-inflammatory indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Development timeline for Prolensa
| Date | Article |
|---|---|
| Apr 8, 2013 | Approval Bausch + Lomb Receives FDA Approval for Prolensa |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
